Connect with us

Technology

Lumia Health™ Debuts World’s First Wearable for Tracking Blood Flow to Your Head at CES 2025

Published

on

 Clinically demonstrated wearable tracks blood flow to your head to help people with chronic illnesses better understand and self-manage symptoms caused by poor blood flow, now backed by $10.4M in funding and strong beta user engagement.

BOSTON, Jan. 6, 2025 /PRNewswire/ — Lumia Health™ is debuting the world’s first wearable that tracks blood flow to the head at CES 2025 (January 7-10) in Eureka Park, Venetian Expo. The Lumia™ wearable is designed to help people better understand and self-manage chronic symptoms of dizziness, brain fog, fatigue, and fainting made worse by standing*. Since emerging from stealth in 2023, the company completed a 30-day $560,000 crowdfunding campaign, sold out of pre-order inventory, secured more than $3.6M in contracts with multiple government agencies, and completed shipments to its Beta customers.

Clinically Shown to have Strong Correlation with Gold Standard Ultrasound and Symptoms

Clinically tested at top institutions like Johns Hopkins, Duke, and Harvard Medical School, Lumia™ technology has been refined by the world’s top experts in blood flow monitoring. Published at the 2024 American Autonomic Society Conference, the Lumia™ technology has been clinically shown to correlate strongly with the gold standard, Transcranial Doppler ultrasound, with a Pearson correlation of 0.91 for Carotid Flow Time, a measure of blood flow to the head. At the 2024 Dysautonomia International Conference, Lumia Flow Index™ was found to correlate better with orthostatic symptoms than traditional heart rate metrics, earning the Patient’s Choice Award.

Usefulness Demonstrated by Strong User Engagement Metrics

Hundreds of Lumia™ Beta testers are already finding immense value in the unprecedented blood flow data, demonstrating exceptional engagement with over 12 hours of daily wear time and over 40 minutes of daily mobile app use, proving its utility as a self-help tool. The biofeedback helps Lumia™ members see how lifestyle factors such as posture, hydration, compression garments, and other daily activities affect blood flow to their head, improving self-awareness and encouraging lifestyle adjustments to avoid exacerbating symptoms.

Unlocking the Next Evolutionary Step in Wearables with All-Day Blood Flow Tracking

The Lumia™ wearable weighs less than 1 gram and is more than 5 times smaller than Apple Airpods. It tracks blood flow by tapping into a shallow artery in the ear, a branch of the External Carotid Artery, which runs parallel to the brain’s primary blood supply. This strong arterial signal is crucial to enabling the wearable’s unprecedented cardiac data. Unlike wrist wearables which suffer from data corruption due to arm movement, the Lumia™ wearable allows users to track blood flow through various activities of daily living. Most users comment that the wearable is so comfortable and unobtrusive that they completely forget they are wearing it.

“Blood flow to the head is the critical missing vital sign for millions suffering from chronic illnesses affected by dizziness, lightheadedness, brain fog, fatigue, and fainting made worse by standing,” said Lumia Health™ Cofounder and CEO, Daniel Lee. “After almost 5 years, we’ve finally unlocked the potential of the ear to track it in a user-friendly wearable, offering unparalleled insights into these often misunderstood illnesses. While we are focused on chronic brain blood flow illnesses to start, our preliminary research shows that multi-day blood flow monitoring also has the potential to revolutionize many of healthcare’s costliest conditions, from fainting and falling in older adults, to improving in-patient fluid management for sepsis and heart failure**. At CES 2025, we are excited to find partners to help us expand the impact that this groundbreaking technology can have.”

From Stealth to CES

Since its launch, Lumia Health has raised $10.4 million in funding, with additional venture financing and government research contracts. The wearable has undergone a variety of clinical pilot tests at top medical institutions, and has been published in the Journal of the American College of Cardiology and the American Autonomic Society.

Join us at booth 62047 in Eureka Park at the Venetian Expo to experience the future of wearables. The team will be offering real-time demos of its blood flow tracking technology. Learn how to rapidly drop the blood flow to your head to experience what dizziness feels like for those with chronic brain blood flow illnesses such as POTS, Dysautonomia, Orthostatic Hypotension, Long COVID, ME/CFS, and Orthostatic Intolerance!

How to Order

Due to high demand, Lumia™ wearables are currently still sold out. Sales will re-open on February 4th at 10AM Eastern, with deliveries starting in March 2025. Save the date and visit www.lumiahealth.com to sign up for email notifications to be among the first to reserve your Lumia™ wearable. Quantities will be limited, and orders will be shipped in the order they are received, so we encourage early reservations to secure your wearable.

About Lumia Health™ 

Lumia Health™, formerly known as STAT Health, is a digital health company improving the quality of life for people living with chronic cardiovascular and neurological diseases, starting with chronic illnesses experiencing drops in blood flow upon standing. Lumia Health™ does this through its hardware platform — the ear wearable – and targeted software programs built atop its unparalleled longitudinal cardiac data. Founded in 2020, Lumia Health™ is backed by leading venture capital firms, government grants, and a growing community of early adopters. The founders, Daniel Lee and Paul Jin, previously ran Bose’s Health Product Innovation Group, and Lee was the inventor of Bose sleepbuds™.

For more information, visit www.lumiahealth.com. For logos, photos and facts, visit our online Media Kit.

*  The initial software app is not intended for medical diagnostic or treatment purposes. It is designed and marketed to comply with the FDA General Wellness Guidance1 and Device Software Functions and Mobile Medical Application Guidance2.

** These proposed indications are research areas under exploration with preliminary feasibility data, and are not cleared or approved by regulatory authorities.

Media Contact
Shivani Ugrin
shivani@lumiahealth.com 
928-614-1065

Click here for more details about our booth at: https://ces25.mapyourshow.com/8_0/exhibitor/exhibitor-details.cfm?exhid=001Pp00000f4LRFIA2.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lumia-health-debuts-worlds-first-wearable-for-tracking-blood-flow-to-your-head-at-ces-2025-302343308.html

SOURCE Lumia Health™

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

The American Legion seeks entries for Fourth Estate Awards in media

Published

on

By

INDIANAPOLIS, Jan. 9, 2025 /PRNewswire/ — The American Legion has announced its call for entries in the annual Fourth Estate Awards competition for excellence in journalism and its positive impact on society. The deadline for submissions to be received or postmarked is March 15, 2025.

The American Legion presents the awards to recognize the outstanding achievements made in print and broadcast media. Website and podcast submissions are also encouraged to compete in the print or broadcast categories. In addition to the award, the winner in each category will be presented a $2,000 stipend to cover travel and lodging expenses to The American Legion National Convention in Tampa. The presentation will occur at approximately 9 am on August 28, 2025 at the Tampa Convention Center.

An entry form with contest rules can be found at https://www.legion.org/information-center/the-fourth-estate-award. You can also contact kchrisman@legion.org for further information.

Submissions are judged on the quality of the work and the impact that it had in producing a positive result for the community. The work must have been published, posted or broadcast in 2024.

All journalists or media outlets who believe their work improved society in a tangible and way are encouraged to submit their entry. There is no entry fee and no single medium is limited to the number of entries.

Past winners include CBS News, CNN, USA Today, WFTS (Tampa) and the Military Times. The complete list can be found at www.legion.org.

Media contacts: Katie Chrisman, (317) 630-1298, kchrisman@legion.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-american-legion-seeks-entries-for-fourth-estate-awards-in-media-302347119.html

SOURCE The American Legion

Continue Reading

Technology

CellFE® and Syenex Collaborate to Advance Cell Engineering with Hybrid Gene Editing Workflow

Published

on

By

ALAMEDA, Calif., Jan. 9, 2025 /PRNewswire/ — CellFE®, a leader in non-viral gene editing technology, and Syenex, a pioneer in enveloped delivery vectors, have announced an innovative collaboration to create a hybrid workflow that seamlessly integrates non-viral and viral approaches to cell therapy engineering. This next-generation process aims to enable streamlined workflows of complex edited cells for biotech and pharmaceutical applications. 

CellFE® and Syenex announce collaboration on hybrid gene editing workflow ahead of the JP Morgan Healthcare Conference.

The collaboration application note will be officially unveiled the week of the highly anticipated J.P. Morgan Healthcare Conference in San Francisco this January, a premier event that brings together industry leaders, investors, and innovators from around the world.

“The market has been anticipating a solution that seamlessly integrates non-viral knockout with viral knockin capabilities into a streamlined workflow—one that preserves cell viability and functionality without compromise.” said Dr. Alla Zamarayeva, CEO of CellFE. “By collaborating with Syenex, we are directly addressing this critical need.”

Jay Rosanelli, CEO at Syenex, added: “This joint effort showcases the role of collaborative science in accelerating the creation of life-changing medicines for patients around the globe. We are thrilled to partner with CellFE and showcase the potential of this novel hybrid workflow to dramatically simplify manufacturing of genetic medicines.”

This collaboration comes at a pivotal time as allogeneic and autologous cell therapy providers seek more efficient manufacturing processes. A key challenge is developing gentler yet highly effective techniques for delivering gene-editing cargo to patient cells, as current methods—often involving viral transduction and electroporation—can be detrimental to cells and extend recovery and processing times, particularly for complex, sequential editing. This innovative hybrid workflow aims to overcome these challenges, enabling advanced genetic editing while preserving cell functionality and supporting streamlined workflows.

Both companies will be attending the J.P. Morgan Healthcare Conference this month from January 13-16th. Details on where to partner with the companies at the conference can be found below, along with contact information for both companies.

Partner with CellFE at the JP Morgan Healthcare Conference:

J.P. Morgan Healthcare Conference – Jan 13-16
Westin St. Francis in San Francisco, CABiotech Showcase – Jan 13-15
Hilton Union Square, San Francisco, CABio Partnering at JPMorgan Week – Jan 13-16
San Francisco Marriott Marquis in San Francisco, CA
cellfebiotech.com/meet

Partner with Syenex at the JP Morgan Healthcare Conference:

Bio Partnering at JPMorgan Week – Jan 13-16
San Francisco Marriott Marquis in San Francisco, CA
syenex.com/meet

About CellFE Biotech
CellFE, a cutting-edge microfluidics company, is transforming the development and manufacturing of lifesaving cell therapies to make them more accessible to patients. CellFE aims to unlock the full potential of this transformative modality by tackling its key market challenges, notably high manufacturing costs and extended vein-to-vein timelines. With a focus on T-Cell, HSC, and iPSC-based therapies, CellFE’s microfluidics-based gene-delivery technology, in conjunction with proprietary best-in-class workflows, targets critical bottlenecks in cell therapy manufacturing. For more information, please visit www.cellfebiotech.com.

About Syenex
Syenex builds bioengineering technologies to unlock the future of human health. Leveraging the power of synthetic biology, we design scalable, precision-engineered gene delivery vectors, empowering cell and gene therapy developers to cure disease and build the next generation of medicines. Designed to break the barriers that slow medical progress, our Open Science model ensures global access to our expanding toolkit and a network of scale-up partners, accelerating the path of breakthroughs from idea to impact for all of academia and biopharma. Since 2022, Syenex has rapidly built a portfolio of cell-specific bioengineering systems and established partnerships across the fields of immune cell, stem cell, and hepatocyte engineering. Learn more and get started at www.syenex.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cellfe-and-syenex-collaborate-to-advance-cell-engineering-with-hybrid-gene-editing-workflow-302347122.html

SOURCE CellFE

Continue Reading

Technology

The TreppWire Podcast Celebrates 300th Episode with Strategic Rebrand and Enhanced Vision

Published

on

By

Trepp announced today a rebrand and enhanced vision for The TreppWire Podcast ahead of its milestone 300th episode.

NEW YORK, Jan. 9, 2025 /PRNewswire-PRWeb/ — Trepp, a leading provider of data, insights, and technology solutions to the structured finance, commercial real estate (CRE), and banking markets announced today a rebrand and enhanced vision for The TreppWire Podcast ahead of its milestone 300th episode.  

“Powered by our marketing, research, and product groups, this show has been a trusted resource for the commercial real estate community, and we are excited to continue its growth,” said Hayley Keen, VP, Head of Marketing.

Since its launch in 2020, The TreppWire Podcast has garnered more than 1.7 million listens, establishing itself as a leading voice in the CRE industry, as well as the structured finance, banking, and broader economic markets. The podcast leverages Trepp’s proprietary commercial property, loan, and financial data and deep market expertise to provide weekly insights to industry professionals.

Complemented by a sleek new visual identity and modern design aesthetic, this strategic rebrand builds upon Trepp’s 40-year legacy of delivering timely, accurate, and comprehensive specialized CRE data and insights to help listeners make better, more informed decisions. Through market cycles, volatility, and periods of growth, The TreppWire Podcast remains committed to uncovering both challenges and opportunities, providing listeners with actionable insights to navigate market dynamics.

The rebrand also introduces an elevated format, which will include frequent industry expert guest appearances, as well as exclusive macroeconomic commentary from Trepp’s newly appointed Chief Economist, Rachel Szymanski. The podcast will continue to be a go-to resource for market participants, delivering timely insights from diverse industry perspectives.

“It is so exciting to watch our podcast hit the 300th episode milestone. Powered by our marketing, research, and product groups, this show has been a trusted resource for the commercial real estate community, and we are excited to continue its growth,” said Hayley Keen, VP, Head of Marketing. “The market has trusted Trepp’s data for more than 40 years, and with this rebrand, we’re not just maintaining that commitment – we’re elevating it. We’re enhancing the podcast experience while staying true to what our audience has always trusted us for: delivering reliable, actionable market intelligence that helps them make informed, confident decisions.”

Listeners can tune in to the newly rebranded The TreppWire Podcast on all major podcast platforms, including Apple Podcasts, Spotify, SoundCloud, and YouTube. Weekly episodes are released every Thursday. Check out our new website to learn more: https://www.trepp.com/the-treppwire-podcast

About Trepp 
Trepp, founded in 1979, is the leading provider of data, insights, and technology solutions to the structured finance, commercial real estate, and banking markets. Trepp provides primary and secondary market participants with the solutions and analytics they need to increase operational efficiencies, information transparency, and investment performance. From its offices in New York, Dallas, and London, Trepp serves its clients with products and services to support trading, research, risk management, surveillance, and portfolio management. Trepp subsidiary, Commercial Real Estate Direct, is a daily news source covering the commercial real estate capital markets. Trepp is owned by the Daily Mail and General Trust (DMGT)

Media Contact

Ennys Soydas, Trepp, Inc., 212-754-1010, press@trepp.com, www.trepp.com

Twitter

View original content to download multimedia:https://www.prweb.com/releases/the-treppwire-podcast-celebrates-300th-episode-with-strategic-rebrand-and-enhanced-vision-302346930.html

SOURCE Trepp, Inc.

Continue Reading

Trending